Hypertension
is a heart-related disease which results in elevated blood pressure in the
arteries. It is also known as arterial hypertension or high blood pressure.
This disease occurs on account of alcohol, smoking, obesity, and other genetic
factors. Although, the disease can be treated with a healthy diet and exercise,
antihypertensives are recommended to control it.
Antihypertensives
are a class of drugs which can prevent hypertension and other
cardiovascular-related disorders like strokes and myocardial infarction. They
are likely to reduce the heart conditions by 21%. Beta blockers, thiazide
diuretics, ACE inhibitors, calcium channel blockers, and angiotensin II
receptor antagonists (ARBs) are the different types of antihypertensive
therapeutics in major developed markets.
Browse Complete Summary Click Here @ http://www.radiantinsights.com/research/antihypertensive-therapeutics-in-major-developed-markets-to-2020-increased-uptake-of-combination-therapies-to-offset-effects-of-key-patent-expiries
Thiazide
diuretics aid in reducing salt and water from the kidneys. They are the first
drugs to be administered for a patient undergoing hypertension treatment. ACE
inhibitors reduce serum creatinine levels better than beta blockers. They are
considered the first line of defense against heart-related disorders. ARBs
reduces the risko f myocardial infarction when combined with amlodipine. Beta
blockers are considered risky and can lead to strokes or type-2 diabetes.
However, they prevent heart attacks in persons who have already experienced a
heart attack.
The
hypertension market was estimated to have earned USD 40 billion of revenue in
2013. The market will attain USD 37 billion by 2020, owing to the patent expiry
of major drugs. It is predicted to grow at a 2.6% CAGR during the period of
2014 to 2017. The market will experience growth on account of fixed-dose
combination (FDCs) drugs, the rising geriatric population, and a low diagnosis
rate.
Related reports by Radiant Insights: http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
FDCs
include Amturnide, Azor, Twynsta, Exforge Tribenzor, Valturna, Benicar HCT,
Tekturna HCT, Tekamlo, and Edarbyclor. New drugs in the pipeline are AHU377 +
valsartan and azilsartan + amlodipine. Patients undergoing the treatment were
known to have reduced levels of blood pressure. Drugs about to lose their
patent are Exforge in 2014, Cozaar in 2010, Tekturna and Tekturna HCT in 2018,
Benicar in 2016, and Atacand and Avapro in 2012.
The
hypertension market has evolved from creating drugs to providing step-by-step
special treatment dependent on the seriousness of the disease. The new classes
of antihypertensive drugs are able to protect the kidneys, liver, heart, and
brain from internal damage.
Table of Contents
Table
of Contents 4
1.1
List of Tables 6
1.2
List of Figures 7
See More Reports of This Category by
Radiant Insights:
·
India Regional Anesthesia Disposables Market Outlook
to 2021 - http://www.radiantinsights.com/research/india-regional-anesthesia-disposables-market-outlook-to-2021
·
India Respiratory Devices Market Outlook to 2021 - http://www.radiantinsights.com/research/india-respiratory-devices-market-outlook-to-2021
2 Introduction 8
2.1
Pathophysiology 8
2.2
Etiology 9
2.3
Signs and Symptoms 9
2.4
Co-Morbidities and Complications 10
2.5
Diagnosis 11
2.5.1
Office Blood Pressure Monitoring 11
2.5.2
Ambulatory Blood Pressure Monitoring 11
2.5.3
Home Blood Pressure Monitoring 11
2.5.4
Miscellaneous Methods 11
2.5.5
Diagnosis of Target Organ Damage 12
2.5.6
Diagnosis of Hypertension in Pregnancy 12
2.6
Classification 12
2.7
Epidemiology 13
2.8
Prognosis 14
2.9
Treatment and Management 14
2.9.1
Treatment Strategy 15
About Radiant Insights
Radiant
Insights is a platform for companies looking to meet their market research and
business intelligence requirements. We assist and facilitate organizations and
individuals procure market research reports, helping them in the decision
making process. We have a comprehensive collection of reports, covering over 40
key industries and a host of micro markets. In addition to over extensive database
of reports, our experienced research coordinators also offer a host of
ancillary services such as, research partnerships/ tie-ups and customized
research solutions.
For More Information, Visit Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Blog URL: http://www.radiantinsightsinc.blogspot.com
No comments:
Post a Comment